PROphylaxis in NOn Major Orthopaedic Surgery

Non-major Orthopaedic Surgery Clinical Trial

— PRONOMOS  

Official title:

A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02401594
• Other study ID #: 1408143
• Secondary ID: 2015-000981-70
• Status: Terminated
• Phase: Phase 3
• Start date: December 8, 2015
• Est. completion date: April 16, 2018

Study information

• Verified date: December 2018
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PRONOMOS is an international multicentre, interventional, parallel, randomised, double-blind non-inferiority study comparing rivaroxaban 10mg od to an active comparator, enoxaparin 4000 UI od in 4040 valid subjects requiring orthopaedic surgery (except low risk such material removal foot surgery or hallux valgus without patient risk factor [6], and major orthopaedic surgeries for femoral neck and trochanteric fractures, THR, TKR)

Pre-randomization treatment with LMWH anticoagulant is allowed for a maximum duration of 24 hours. However, only a single pre-randomization dose of LMWH is allowed. After randomization, patients allocated to the rivaroxaban arm will receive rivaroxaban 10 mg once-daily started 6-10 hours provided haemostasis has been established after surgery or 24h hours after LMWH injection if needed for the intended treatment duration of 2 to 12 weeks based on medical judgment (according to immobilization). Patients allocated to the comparator arm will receive enoxaparin once daily for the same intended treatment duration. All patients will have a 30-day observational period after cessation of treatment.

Description:

Major orthopedic surgery (hip, knee replacements and hip fracture) represents only a small part of all orthopaedic surgery procedures. Procedures for trauma patients and orthopaedic lower limb surgery without trauma are much more frequent (tibia osteotomy, arthrodesis, ligament repair….).

The incidence of trauma patients requiring surgery and prolonged immobilisation is rising, mainly because of the increasing popularity of recreational sports. However, the epidemiology and prevention of VTE after such injuries have been poorly studied. The combination of limb surgery with or without trauma in orthopaedic surgery is responsible for an increase in venous thromboembolism (VTE). Usually, surgery of lower limb is considered as moderate or high risk for DVT with different duration related to immobilisation. For instance tibia osteotomy is at very high risk during at least 6 weeks and knee arthroscopy for ligament repair is at moderate risk during 10 days. However LMWH is recommended in both surgeries. Non-major orthopaedic surgery represents a major additional risk factor by itself; therefore such patients undergoing surgery deserve to receive VTE prophylaxis.

Rivaroxaban is a new oral anticoagulant developing a potent anti-Xa activity. In major orthopaedic surgery, it has shown to be more effective and as safe as LMWH (Enoxaparin 4000 IU once daily) in THR and TKR patients (RECORD program). Up to now, pending the limited number of surgical settings in which it has been developed in orthopaedic surgery, it is only approved for the prevention of venous thromboembolism (VTE) in THR and TKR procedures, which represent only 20% of all orthopaedic interventions. Non-major elective lower limb surgery and traumatology population is younger as compared to prosthetic orthopaedic surgery patients. Fewer VTE and cardiovascular events are to be feared. These patients receive quite often injectable thromboprophylaxis for a total duration lying between approximately 6 weeks to 3 months. In the one hand, the risk of major bleeding is low in this younger population. On the other hand, compliance and cost should be in favour of Rivaroxaban, because no injection and no platelets counts are needed.

The results of Xamos descriptive sub-analysis in non-elective (fracture related) orthopaedic surgery are consistent with the overall results of Xamos and are in favour of further investigations in this area. In this small subset of patients (n=790), the incidence of symptomatic thromboembolic events observed was low in patients treated with Xarelto and the overall frequency of treatment emergent major bleedings was low in both groups and serious adverse events occurred less frequently in patients treated with Xarelto. Therefore, collection of clinical data in this population is needed and awaited by many orthopaedic surgeons and anaesthetists in charge of VTE prophylaxis.

The population with femoral neck and trochanteric fracture is a specific one with different characteristics, elderly, frail and with a higher bleeding risk. This population will be excluded.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3608
• Est. completion date: April 16, 2018
• Est. primary completion date: April 11, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed and dated informed consent form,

2. Age = 18 years,

3. Hospitalised for non-major orthopaedic surgery and requiring thromboprophylaxis according to the investigator's judgement on VTE risk such Achilles' repair, hip (except femoral neck and trochanteric fracture), knee, tibial plateau, femur (non femoral head), tibial and ankle fractures and tibial osteotomy, tibial transposition, arthrodesis of leg articulation, ligament repair of the knee or the ankle or any elective orthopaedic limb surgery requiring thromboprophylaxis).

Exclusion Criteria:

1. Major orthopaedic surgery Hip and Knee replacement, femoral neck and trochanteric fractures, spine surgery,

2. Low risk surgery without patient VTE risk: foot surgery (Hallux Valgus), material removal,

3. Delay between hospitalisation and randomisation greater than two days,

4. Women of childbearing potential not using a reliable contraceptive method throughout the study period (a list of reliable contraceptive methods is provided in the accompanying SPM),

5. Women pregnant or breast-feeding during the study period,

6. Body weight less than 50 kg (to avoid bleeding over risk) or over 120 kg,

7. Long term treatment with VKA therapy or NOAC,

8. Concomitant treatment with clopidogrel, prasugrel and ticagrelor,

9. Platelet count < 100 Giga/L,

10. Documented history of acquired or inherited bleeding disorder (e.g., von Willebrand's disease),

11. Severe renal failure with calculated creatinine clearance (Cockcroft Formula) < 30 mL/min,

12. Severe hepatic insufficiency with prothrombin time < 60% or liver impairment associated with coagulation disorders,

13. History of thrombocytopenia,

14. Any other current significant medical condition that might interfere with treatment evaluation according to the investigator's judgement,

15. Known hypersensitivity or other severe reaction to any component of the investigational medicinal product(s),

16. Participation in another clinical study involving an investigational medicinal product within 30 days prior to inclusion or concomitantly with this study,

17. Active bleeding or contraindication to anticoagulant therapy

18. Chronic alcoholic intoxication,

19. Anticipated poor compliance of subject with study procedures

Related Conditions & MeSH terms

• Non-major Orthopaedic Surgery

Intervention

Drug:
• Rivaroxaban
10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
• Enoxaparin
A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.

Locations

Country	Name	City	State
France	CHU AMIENS Picardie	Amiens
France	CHU Angers	Angers
France	Clinique Générale d'ANNECY	Annecy
France	CHU BESANCON- Hôpital Jean Minjoz	Besancon
France	Hopital Ambroise Pare	Boulogne Billancourt
France	Médipôle de Savoie	Challes Les Eaux
France	Clinique Léonard de Vinci	Chambray Les Tours
France	CHU de Dijon- Bocage	Dijon
France	Hôpitaux Universitaires de Strasbourg C.C.O.M	Illkirch-Graffenstaden
France	CHU de Grenoble 6 Hôpital Michallon	La Tronche
France	Chu Kremlin Bicetre	Le Kremlin Bicetre
France	CHRU Lille -Hôpital Roger Sallengro	Lille
France	CHU Dupuytren	Limoges
France	Ch Lyon Sud Pierre Benite	Lyon
France	Ch Les Chanaux	Macon
France	Chu Marseille La Timone	Marseille
France	CHU de MONTPELLIER - Lapeyronnie	Montpellier
France	CHRU NANTES - Hôtel Dieu	Nantes
France	CHU Carémeau	Nîmes
France	Ch Paris Pitie Salpetriere	Paris
France	Ch Saint Louis-Lariboisiere	Paris
France	Clinique ARAGO	Paris
France	GH Paris Saint-Joseph	Paris
France	Hopital Cochin	Paris
France	Hopital Europeen Georges POMPIDOU	Paris
France	CHU Bordeaux	Pessac
France	Polyclynique de Poitiers	Poitiers
France	CHU de Reims - Hôpital MAsion Blanche	Reims
France	Hôpital Robert Debré	Reims
France	CHU de Rennes - Hôpital Pontchaillou	Rennes
France	CHU de Rouen	Rouen
France	Chp Saint Gregoire	Saint Gregoire
France	CHU de SAINT-ETIENNE	Saint-etienne
France	Clinique de la Mutualiste	Saint-etienne
France	Polyclinique Du Parc	Saint-saulve
France	CHRU de Strasbourg- Hôpital Hautepierre	Strasbourg
France	CHU Toulouse - Hôpital Pierre-Paul Riquet	Toulouse
France	Clinique Médipôle	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Saint Etienne	Bayer

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major VTE	composite of proximal DVT (asymptomatic and symptomatic) assessed by ultrasonography, symptomatic events (distal and proximal DVT, PE) and VTE related deaths.; The treatment period ranges from 15 days to 3 months depending on the type of surgery	From date of randomization until the date of the end of the treatment period (up to 3 months maximum).
Secondary	Major bleeding	bleeding event that meets at least one of the following criteria [5]: fatal bleeding; critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal); clinically overt bleeding (at surgical or extrasurgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L) compared with the pre-randomization level; clinically overt bleeding (at surgical or extrasurgical site) leading to transfusion of two or more units of whole blood or packed cells; bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room) The treatment period ranges from 15 days to 3 months depending on the type of surgery	From date of randomization until the date of the end of the treatment period (up to 3 months maximum).
Secondary	Clinically relevant non-major bleeding	overt bleeding not meeting the criteria for major bleeding and corresponds to any bleeding necessitating medical intervention or a specific, unscheduled consultation or treatment discontinuation, or resulting in a deterioration of the subject's quality of life. Some examples of clinically significant bleeding are given below: Epistaxis that lasts more than five minutes or recurrent or necessitates packing,; Spontaneous macroscopic haematuria or haematuria lasting more than 24 hours after instrumentation,; Gastrointestinal haemorrhage (melena or rectorrhagia),; Haemoptysis,; Subcutaneous haematoma > 100 cm². The treatment period ranges from 15 days to 3 months depending on the type of surgery	From date of randomization until the date of the end of the treatment period (up to 3 months maximum)..
Secondary	Overt thrombocytopenia	platelet count <100 giga/L or fall = 50% of the platelet count as compared with the first post-operative count which will be done as local lab for all centres The treatment period ranges from 15 days to 3 months depending on the type of surgery	From date of randomization until the date of the end of the treatment period (up to 3 months maximum)..
Secondary	Mortality	All cause mortality The treatment period ranges from 15 days to 3 months depending on the type of surgery	From date of randomization until the date of the end of the treatment period (up to 3 months maximum)..